Dr Reddys Labs Financials

RDY

FY2026 annual

Revenue $3.6B -6.1% YoY

Net Income $452.0M -32.6% YoY

EPS (Diluted) Not reported for FY2026

Free Cash Flow $358.0M +60.5% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended May 29, 2026 Reported May 29, 2026 Currency USD FYE May

Dr Reddys Labs (RDY) reported $3.6B in revenue for fiscal year 2026, down 6.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RDY FY2026 2026-08-15

Revenue growth has given way to a lower-margin year, while cash generation remains shaped by capital spending rather than earnings alone.

From FY2025 to FY2026, revenue fell from $3.81B to $3.58B, so the latest profit pressure reflects a smaller business base rather than an isolated margin movement. Net profit margin fell from 17.6% to 12.6%, indicating that profitability weakened faster than sales and that the business retained less profit from each dollar of revenue.

Free cash flow rose from $223M to $358M despite lower FY2026 net income. The rebound appears tied more to lighter capital spending than stronger earnings, making cash conversion partly dependent on investment timing.

Liquidity has tightened as the current ratio declined from 2.6x to 1.8x, even though the company remains equity-funded. Cash of $164M covers only a fraction of $1.79B in current liabilities, so day-to-day flexibility depends more on continued operating inflows than cash reserves alone.

Financial Health Signals

Financial Health Score 36/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Dr Reddys Labs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Not available for Dr Reddys Labs, and counted as zero in the overall score.

Growth

Dr Reddys Labs's revenue declined 6.1% year-over-year, from $3.8B to $3.6B. This contraction results in a growth score of 43/100.

Leverage

Dr Reddys Labs has a moderate D/E ratio of 0.52. This balance of debt and equity financing earns a leverage score of 59/100.

Liquidity

Dr Reddys Labs's current ratio of 1.80 indicates adequate short-term liquidity, earning a score of 52/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Dr Reddys Labs has a free cash flow margin of 10.0%, earning a moderate score of 64/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Not available for Dr Reddys Labs, and counted as zero in the overall score.

Piotroski F-Score Partial

3/7

Dr Reddys Labs passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.34x

For every $1 of reported earnings, Dr Reddys Labs generates $1.34 in operating cash flow ($607.0M OCF vs $452.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.6B

YoY-6.1%

5Y CAGR+6.7%

Dr Reddys Labs generated $3.6B in revenue in fiscal year 2026. This represents a decrease of 6.1% from the prior year.

Net Income

$452.0M

YoY-32.6%

5Y CAGR+13.9%

Dr Reddys Labs reported $452.0M in net income in fiscal year 2026. This represents a decrease of 32.6% from the prior year.

EBITDA

Not reported for fiscal year 2026.

EPS (Diluted)

Not reported for fiscal year 2026.

Cash & Balance Sheet

Free Cash Flow

$358.0M

YoY+60.5%

5Y CAGR+0.2%

Dr Reddys Labs generated $358.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 60.5% from the prior year.

Cash & Debt

$164.0M

YoY-4.7%

5Y CAGR-4.2%

Dr Reddys Labs held $164.0M in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

835M

YoY0.0%

Dr Reddys Labs had 835M shares outstanding in fiscal year 2026. That is unchanged from the prior year.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Net Margin

12.6%

YoY-5.0pp

5Y CAGR+3.5pp

Dr Reddys Labs's net profit margin was 12.6% in fiscal year 2026, showing the share of revenue converted to profit. This is down 5.0 percentage points from the prior year.

Return on Equity

11.2%

YoY-5.9pp

5Y CAGR+1.2pp

Dr Reddys Labs's ROE was 11.2% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2026.

Operating Margin

Not reported for fiscal year 2026.

Capital Allocation

Capital Expenditures

$249.0M

YoY-22.7%

5Y CAGR+13.4%

Dr Reddys Labs invested $249.0M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 22.7% from the prior year.

R&D Spending

Not reported for fiscal year 2026.

Share Buybacks

Not reported for fiscal year 2026.

RDY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RDY quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Revenue	$3.6B-6.1%	$3.8B+13.8%	$3.4B+12.0%	$3.0B+5.9%	$2.8B+8.9%	$2.6B+12.0%	$2.3B+4.1%	$2.2B+2.0%	$2.2B
Interest Expense	$44.0M-20.0%	$55.0M+14.6%	$48.0M+37.1%	$35.0M+25.0%	$28.0M+21.7%	$23.0M+15.0%	$20.0M+25.0%	$16.0M-50.0%	$32.0M
Income Tax	$132.0M-42.4%	$229.0M+18.0%	$194.0M+4.3%	$186.0M+61.7%	$115.0M-8.0%	$125.0M+757.9%	-$19.0M-135.8%	$53.0M-24.3%	$70.0M
Net Income	$452.0M-32.6%	$671.0M+0.4%	$668.0M+21.9%	$548.0M+76.2%	$311.0M+31.8%	$236.0M-8.9%	$259.0M-4.8%	$272.0M+80.1%	$151.0M

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).

RDY Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RDY quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$6.2B+7.0%	$5.8B+24.1%	$4.7B+18.7%	$3.9B+1.5%	$3.9B+6.3%	$3.6B+17.8%	$3.1B-5.5%	$3.3B-5.9%	$3.5B
Current Assets	$3.2B+9.9%	$2.9B-1.6%	$3.0B+18.2%	$2.5B+5.0%	$2.4B+18.3%	$2.0B+17.2%	$1.7B+4.4%	$1.7B-1.7%	$1.7B
Cash & Equivalents	$164.0M-4.7%	$172.0M+102.4%	$85.0M+21.4%	$70.0M-64.3%	$196.0M-3.4%	$203.0M+651.9%	$27.0M-15.6%	$32.0M-22.0%	$41.0M
Inventory	$816.0M-1.9%	$832.0M+9.0%	$763.0M+28.9%	$592.0M-11.8%	$671.0M+8.1%	$621.0M+33.5%	$465.0M-4.3%	$486.0M+8.7%	$447.0M
Accounts Receivable	$1.1B+2.0%	$1.1B+9.9%	$963.0M+9.2%	$882.0M+0.2%	$880.0M+29.6%	$679.0M+1.8%	$667.0M+15.8%	$576.0M-7.7%	$624.0M
Goodwill	$137.0M-0.7%	$138.0M+170.6%	$51.0M-1.9%	$52.0M-10.3%	$58.0M-6.5%	$62.0M+17.0%	$53.0M-5.4%	$56.0M-8.2%	$61.0M
Total Liabilities	$2.1B+16.2%	$1.8B+42.1%	$1.3B+16.1%	$1.1B-18.0%	$1.3B+6.6%	$1.3B+23.3%	$1.0B-16.8%	$1.2B-19.1%	$1.5B
Current Liabilities	$1.8B+17.0%	$1.5B+32.6%	$1.2B+10.3%	$1.0B-15.7%	$1.2B+8.7%	$1.1B+18.0%	$966.0M+11.9%	$863.0M-19.3%	$1.1B
Total Equity	$4.1B+2.7%	$3.9B+17.3%	$3.4B+19.8%	$2.8B+11.9%	$2.5B+6.1%	$2.4B+15.1%	$2.1B+1.4%	$2.0B+4.4%	$1.9B
Retained Earnings	$3.8B+1.5%	$3.7B+16.1%	$3.2B+21.3%	$2.6B+13.3%	$2.3B+8.6%	$2.1B+11.5%	$1.9B+2.8%	$1.9B+6.3%	$1.7B

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Total Assets	$5.8B+24.1%	$4.7B+18.7%	$3.9B+1.5%	$3.9B+6.3%	$3.6B+17.8%	$3.1B-5.5%	$3.3B-5.9%	$3.5B
Current Assets	$2.9B-1.6%	$3.0B+18.2%	$2.5B+5.0%	$2.4B+18.3%	$2.0B+17.2%	$1.7B+4.4%	$1.7B-1.7%	$1.7B
Cash & Equivalents	$172.0M+102.4%	$85.0M+21.4%	$70.0M-64.3%	$196.0M-3.4%	$203.0M+651.9%	$27.0M-15.6%	$32.0M-22.0%	$41.0M
Inventory	$832.0M+9.0%	$763.0M+28.9%	$592.0M-11.8%	$671.0M+8.1%	$621.0M+33.5%	$465.0M-4.3%	$486.0M+8.7%	$447.0M
Accounts Receivable	$1.1B+9.9%	$963.0M+9.2%	$882.0M+0.2%	$880.0M+29.6%	$679.0M+1.8%	$667.0M+15.8%	$576.0M-7.7%	$624.0M
Goodwill	$138.0M+170.6%	$51.0M-1.9%	$52.0M-10.3%	$58.0M-6.5%	$62.0M+17.0%	$53.0M-5.4%	$56.0M-8.2%	$61.0M
Total Liabilities	$1.8B+42.1%	$1.3B+16.1%	$1.1B-18.0%	$1.3B+6.6%	$1.3B+23.3%	$1.0B-16.8%	$1.2B-19.1%	$1.5B
Current Liabilities	$1.5B+32.6%	$1.2B+10.3%	$1.0B-15.7%	$1.2B+8.7%	$1.1B+18.0%	$966.0M+11.9%	$863.0M-19.3%	$1.1B
Total Equity	$3.9B+17.3%	$3.4B+19.8%	$2.8B+11.9%	$2.5B+6.1%	$2.4B+15.1%	$2.1B+1.4%	$2.0B+4.4%	$1.9B
Retained Earnings	$3.7B+16.1%	$3.2B+21.3%	$2.6B+13.3%	$2.3B+8.6%	$2.1B+11.5%	$1.9B+2.8%	$1.9B+6.3%	$1.7B

Not reported in any period shown, so not listed: Long-Term Debt.

RDY Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RDY quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	$607.0M+11.4%	$545.0M0.0%	$545.0M-23.9%	$716.0M+93.5%	$370.0M-24.2%	$488.0M+23.2%	$396.0M-4.6%	$415.0M+49.8%	$277.0M
Capital Expenditures	$249.0M-22.7%	$322.0M+63.5%	$197.0M+42.8%	$138.0M-28.5%	$193.0M+45.1%	$133.0M+107.8%	$64.0M-36.6%	$101.0M-29.4%	$143.0M
Free Cash Flow	$358.0M+60.5%	$223.0M-35.9%	$348.0M-39.8%	$578.0M+226.6%	$177.0M-50.1%	$355.0M+6.9%	$332.0M+5.7%	$314.0M+134.3%	$134.0M
Investing Cash Flow	-$700.0M-2.6%	-$682.0M-41.2%	-$483.0M+4.0%	-$503.0M-44.5%	-$348.0M-12.3%	-$310.0M-376.9%	-$65.0M+42.0%	-$112.0M+51.1%	-$229.0M
Financing Cash Flow	$88.0M-60.4%	$222.0M+593.3%	-$45.0M+86.2%	-$327.0M-921.9%	-$32.0M-700.0%	-$4.0M+98.8%	-$334.0M-8.4%	-$308.0M-352.9%	-$68.0M
Dividends Paid	$71.0M-9.0%	$78.0M-2.5%	$80.0M+31.1%	$61.0M+10.9%	$55.0M-3.5%	$57.0M+9.6%	$52.0M-10.3%	$58.0M-4.9%	$61.0M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$8.0M	N/A

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18

Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

RDY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

RDY quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Net Margin	12.6%-5.0pp	17.6%-2.3pp	19.9%+1.6pp	18.3%+7.3pp	11.0%+1.9pp	9.1%-2.1pp	11.2%-1.0pp	12.2%+5.3pp	6.9%
Return on Equity	11.2%-5.9pp	17.0%-2.8pp	19.9%+0.4pp	19.5%+7.1pp	12.4%+2.4pp	10.0%-2.6pp	12.6%-0.8pp	13.4%+5.6pp	7.8%
Return on Assets	7.3%-4.3pp	11.6%-2.7pp	14.4%+0.4pp	14.0%+5.9pp	8.1%+1.6pp	6.5%-1.9pp	8.4%+0.1pp	8.3%+4.0pp	4.4%
Current Ratio	1.80-0.1x	1.92-0.7x	2.58+0.2x	2.41+0.5x	1.93+0.2x	1.780.0x	1.79-0.1x	1.92+0.3x	1.57
Debt-to-Equity	0.52+0.1x	0.46+0.1x	0.380.0x	0.39-0.1x	0.540.0x	0.530.0x	0.50-0.1x	0.61-0.2x	0.78
FCF Margin	10.0%+4.2pp	5.9%-4.5pp	10.4%-8.9pp	19.3%+13.1pp	6.3%-7.4pp	13.7%-0.7pp	14.3%+0.2pp	14.1%+8.0pp	6.1%

Metric	Q4'25	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18
Current Ratio	1.92-0.7x	2.58+0.2x	2.41+0.5x	1.93+0.2x	1.780.0x	1.79-0.1x	1.92+0.3x	1.57
Debt-to-Equity	0.46+0.1x	0.380.0x	0.39-0.1x	0.540.0x	0.530.0x	0.50-0.1x	0.61-0.2x	0.78

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.

Similar Companies

Viatris Inc VTRS

$19.2B

Neurocrine Biosciences Inc NBIX

$15.6B

Teva Pharm TEVA

$44.4B

United Therapeutics Corp. UTHR

$22.2B

Takeda Pharm TAK

$58.6B

Where Dr Reddys Labs Ranks

Frequently Asked Questions

What is Dr Reddys Labs's annual revenue?

Dr Reddys Labs (RDY) reported $3.6B in total revenue for fiscal year 2026. This represents a -6.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Dr Reddys Labs's revenue growing?

Dr Reddys Labs (RDY) revenue declined by 6.1% year-over-year, from $3.8B to $3.6B in fiscal year 2026.

Is Dr Reddys Labs profitable?

Yes, Dr Reddys Labs (RDY) reported a net income of $452.0M in fiscal year 2026, with a net profit margin of 12.6%.

What is Dr Reddys Labs's net profit margin?

Dr Reddys Labs (RDY) had a net profit margin of 12.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Dr Reddys Labs's return on equity (ROE)?

Dr Reddys Labs (RDY) has a return on equity of 11.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Dr Reddys Labs's free cash flow?

Dr Reddys Labs (RDY) generated $358.0M in free cash flow during fiscal year 2026. This represents a 60.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Dr Reddys Labs's operating cash flow?

Dr Reddys Labs (RDY) generated $607.0M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Dr Reddys Labs's total assets?

Dr Reddys Labs (RDY) had $6.2B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Dr Reddys Labs's capital expenditures?

Dr Reddys Labs (RDY) invested $249.0M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How many shares does Dr Reddys Labs have outstanding?

Dr Reddys Labs (RDY) had 835M shares outstanding as of fiscal year 2026.

What is Dr Reddys Labs's current ratio?

Dr Reddys Labs (RDY) had a current ratio of 1.80 as of fiscal year 2026, which is generally considered healthy.

What is Dr Reddys Labs's debt-to-equity ratio?

Dr Reddys Labs (RDY) had a debt-to-equity ratio of 0.52 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dr Reddys Labs's return on assets (ROA)?

Dr Reddys Labs (RDY) had a return on assets of 7.3% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Dr Reddys Labs's Piotroski F-Score?

Dr Reddys Labs (RDY) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dr Reddys Labs's earnings high quality?

Dr Reddys Labs (RDY) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Dr Reddys Labs?

Dr Reddys Labs (RDY) scores 36 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.